logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 20 of 23 Items
Showing 1 - 20 of 23 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Case Report/Series

Chronic high level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in North-West Ethiopia: potential superspreaders?

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-01-09 • Clinical Infectious Diseases
2024-01-09 • Clinical Infectious Diseases
BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
Journal Article
|
Review

The status of combination therapy for visceral leishmaniasis: an updated review

van Griensven J, Dorlo TPC, Diro EGJ, Costa CH, Burza S
2024-01-01 • Lancet Infectious Diseases
2024-01-01 • Lancet Infectious Diseases
For the past 15 years, trials of combination therapy options for visceral leishmaniasis have been conducted with the aim of identifying effective, and safe treatment regimens that were s...
Journal Article
|
Commentary

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia

Boodman C, van Griensven J, Gupta N, Diro EGJ, Ritmeijer KKD
2023-03-23 • PLOS Neglected Tropical Diseases
2023-03-23 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia

Abongomera C, Ritmeijer KKD, Vogt F, Buyze J, Mekonnen Z,  et al.
2017-06-05 • PLOS One
2017-06-05 • PLOS One
BACKGROUND
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
Journal Article
|
Research

Visceral leishmaniasis and HIV coinfection in East Africa

Diro EGJ, Lynen L, Ritmeijer KKD, Boelaert M, Hailu ADE,  et al.
2014-06-26 • PLOS Neglected Tropical Diseases
2014-06-26 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload a...
Journal Article
|
Research

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study

Abongomera C, Diro EGJ, de Lima Pereira A, Buyze J, Stille K,  et al.
2018-05-25 • PLOS Neglected Tropical Diseases
2018-05-25 • PLOS Neglected Tropical Diseases
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and...
Protocol
|
Research Protocol

Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

Diro EGJ, Griensven JV, Woldegebreal T, Belew Z, Taye M,  et al.
2018-07-01
2018-07-01
2.1 OBJECTIVES
2.1.1 General objective:

To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients t...
Protocol
|
Research Protocol

Predicting Visceral Leishmaniasis in HIV Infected Patients (PreLeisH)

Griensven JV, Diro EGJ
2018-07-01
2018-07-01
Aim To study the asymptomatic period preceding the onset of active VL in HIV‐infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence‐based screen and...
Journal Article
|
Commentary

Visceral Leishmaniasis as an AIDS defining condition: towards consistency across WHO guidelines

van Griensven J, Ritmeijer KKD, Lynen L, Diro EGJ
2014-07-17 • PLOS Neglected Tropical Diseases
2014-07-17 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Effect of the 2014/2015 Ebola outbreak on reproductive health services in a rural district of Guinea: an ecological study

Camara BS, Delamou A, Diro EGJ, Beavogui A, El Ayadi AM,  et al.
2017-03-18 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2017-03-18 • Transactions of the Royal Society of Tropical Medicine and Hygiene
BACKGROUND
The 2014/2015 Ebola outbreak was the most sustained in history. In Guinea, we compared trends in family planning, antenatal care, and institutional deliveries over the per...
Journal Article
|
Commentary

Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line

Addisu A, Adriaensen W, Balew A, Asfaw M, Diro EGJ,  et al.
2019-02-08 • BMJ Global Health
2019-02-08 • BMJ Global Health
SUMMARY BOX

The international community has pledged through the Sustainable Development Goals to eliminate neglected tropical diseases by 2030.

Authors from 19 institut...
Protocol
|
Research Protocol

A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine

Hailu ADE, Diro EGJ, Kolja S, Ritmeijer KKD, Yifru S,  et al.
2018-07-01
2018-07-01
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Journal Article
|
Research

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|
Research

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...
Journal Article
|
Research

Influence of the 2014-2015 Ebola Outbreak on the Vaccination of Children in a Rural District of Guinea

Camara BS, Delamou A, Diro EGJ, El Ayadi AM, Béavogui AH,  et al.
2017-06-21 • Public Health Action
2017-06-21 • Public Health Action
Setting: All health centres in Macenta District, rural Guinea. Objective: To compare stock-outs of vaccines, vaccine stock cards and the administration of various childhood vaccines acro...
Journal Article
|
Research

Leishmania antigenuria to predict initial treatment failure and relapse in visceral leishmaniasis/HIV coinfected patients: an exploratory study nested within a clinical trial in Ethiopia

van Griensven J, Mangesha B, Mekonnen T, Fikre H, Takele Y,  et al.
2018-03-29 • Frontiers in Cellular and Infection Microbiology
2018-03-29 • Frontiers in Cellular and Infection Microbiology
BACKGROUND
Biomarkers predicting the risk of VL treatment failure and relapse in VL/HIV coinfected patients are needed. Nested within a two-site clinical trial in Ethiopia (2011-2015...
Journal Article
|
Research

Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in northwest Ethiopia?

Aderie EM, Diro EGJ, Zachariah R, da Fonseca M, Abongomera C,  et al.
2017-06-13 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2017-06-13 • Transactions of the Royal Society of Tropical Medicine and Hygiene
BACKGROUND
Visceral leishmaniasis (VL) patients with HIV co-infection should receive antiretroviral treatment (ART). However, the best timing for initiation of ART is not known. Amon...
Journal Article
|
Research

The risk and predictors of visceral leishmaniasis relapse in HIV co-infected patients in Ethiopia: a retrospective cohort study

Abongomera C, Diro EGJ, Vogt F, Tsoumanis A, Mekonnen Z,  et al.
2017-10-30 • Clinical Infectious Diseases
2017-10-30 • Clinical Infectious Diseases
BACKGROUND
East Africa, where Leishmania donovani is prevalent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) coinfection...
Journal Article
|
Research

Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial

Diro EGJ, Ritmeijer KKD, Boelaert M, Alves F, Mohammed R,  et al.
2017-09-13 • Clinical Infectious Diseases
2017-09-13 • Clinical Infectious Diseases
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 m...
Journal Article
|
Research

Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?

van Griensven J, Mohammed R, Ritmeijer KKD, Burza S, Diro EGJ
2018-03-16 • Open Forum Infectious Diseases
2018-03-16 • Open Forum Infectious Diseases
Visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection remains a major problem in Ethiopia, India, and Brazil. Tuberculosis (TB), a treatable factor, could contribute...